Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT06172296
Registration number
NCT06172296
Ethics application status
Date submitted
13/12/2023
Date registered
15/12/2023
Date last updated
16/07/2025
Titles & IDs
Public title
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Query!
Scientific title
A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma
Query!
Secondary ID [1]
0
0
NCI-2023-08530
Query!
Secondary ID [2]
0
0
NCI-2023-08530
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Ganglioneuroblastoma, Nodular
0
0
Query!
Neuroblastoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Neuroendocrine tumour (NET)
Query!
Cancer
0
0
0
0
Query!
Children's - Other
Query!
Cancer
0
0
0
0
Query!
Children's - Brain
Query!
Cancer
0
0
0
0
Query!
Brain
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Surgery - Biospecimen Collection
Treatment: Surgery - Bone Marrow Aspiration
Treatment: Surgery - Bone Marrow Biopsy
Treatment: Drugs - Carboplatin
Treatment: Drugs - Cisplatin
Treatment: Surgery - Computed Tomography
Treatment: Drugs - Cyclophosphamide
Treatment: Other - Dinutuximab
Treatment: Drugs - Doxorubicin
Treatment: Surgery - Echocardiography Test
Treatment: Drugs - Etoposide
Treatment: Surgery - FDG-Positron Emission Tomography and Computed Tomography Scan
Treatment: Surgery - Hematopoietic Cell Transplantation
Treatment: Drugs - Irinotecan
Treatment: Drugs - Isotretinoin
Treatment: Surgery - Leukapheresis
Treatment: Surgery - Magnetic Resonance Imaging
Treatment: Drugs - Melphalan
Treatment: Surgery - Multigated Acquisition Scan
Treatment: Other - Radiation Therapy
Treatment: Surgery - Radionuclide Imaging
Other interventions - Survey Administration
Treatment: Drugs - Temozolomide
Treatment: Drugs - Thiotepa
Treatment: Drugs - Topotecan
Treatment: Surgery - Tumor Resection
Treatment: Drugs - Vincristine
Active comparator: Arm A (SOC treatment) - See detailed description
Experimental: Arm B (Dinutuximab in induction) - See detailed description
Treatment: Surgery: Biospecimen Collection
Undergo blood and urine sample collection
Treatment: Surgery: Bone Marrow Aspiration
Undergo bone marrow aspiration
Treatment: Surgery: Bone Marrow Biopsy
Undergo bone marrow biopsy
Treatment: Drugs: Carboplatin
Given IV
Treatment: Drugs: Cisplatin
Given IV
Treatment: Surgery: Computed Tomography
Undergo CT scan
Treatment: Drugs: Cyclophosphamide
Given IV
Treatment: Other: Dinutuximab
Given IV
Treatment: Drugs: Doxorubicin
Given IV
Treatment: Surgery: Echocardiography Test
Undergo ECHO
Treatment: Drugs: Etoposide
Given IV
Treatment: Surgery: FDG-Positron Emission Tomography and Computed Tomography Scan
Undergo FDG PET
Treatment: Surgery: Hematopoietic Cell Transplantation
Undergo stem cell infusion
Treatment: Drugs: Irinotecan
Given IV
Treatment: Drugs: Isotretinoin
Given PO
Treatment: Surgery: Leukapheresis
Undergo apheresis
Treatment: Surgery: Magnetic Resonance Imaging
Undergo MRI
Treatment: Drugs: Melphalan
Given IV
Treatment: Surgery: Multigated Acquisition Scan
Undergo MUGA
Treatment: Other: Radiation Therapy
Undergo radiation therapy
Treatment: Surgery: Radionuclide Imaging
Undergo I-MIBG scan
Other interventions: Survey Administration
Ancillary studies
Treatment: Drugs: Temozolomide
Given PO or via NG or G tube
Treatment: Drugs: Thiotepa
Given IV
Treatment: Drugs: Topotecan
Given IV
Treatment: Surgery: Tumor Resection
Undergo tumor resection surgery
Treatment: Drugs: Vincristine
Given IV
Query!
Intervention code [1]
0
0
Treatment: Surgery
Query!
Intervention code [2]
0
0
Treatment: Drugs
Query!
Intervention code [3]
0
0
Treatment: Other
Query!
Intervention code [4]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Event free survival (EFS)
Query!
Assessment method [1]
0
0
EFS time is calculated from time of randomization to Arms A or B to first episode of disease relapse or progression, second malignancy, or death, or until last contact if no event has occurred.
Query!
Timepoint [1]
0
0
Up to 3 years
Query!
Secondary outcome [1]
0
0
End of Induction (EOI) response rate
Query!
Assessment method [1]
0
0
The response rate will be calculated among all evaluable patients at end of Induction. Responders are defined as patients who achieve a \>= partial response per the revised 2017 International Neuroblastoma Response Criteria (INRC)
Query!
Timepoint [1]
0
0
From randomization to end of extended Induction, up to 12 months
Query!
Secondary outcome [2]
0
0
Overall survival (OS)
Query!
Assessment method [2]
0
0
OS time is calculated from time of randomization to Arms A or B until death, or until last contact if patient is alive.
Query!
Timepoint [2]
0
0
Up to 3 years
Query!
Secondary outcome [3]
0
0
Incidence of adverse events
Query!
Assessment method [3]
0
0
The proportion of patients with at least one grade 3 or higher non-hematologic toxicity or grade 4 or higher hematologic toxicity during protocol therapy, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0, will be reported.
Query!
Timepoint [3]
0
0
Up to 2 years
Query!
Secondary outcome [4]
0
0
GD2 expression
Query!
Assessment method [4]
0
0
Dinutuximab binding to pre-therapy patient tumor samples will be measured and categorized as high or low.
Query!
Timepoint [4]
0
0
Up to 12 months
Query!
Eligibility
Key inclusion criteria
* Patients must be enrolled on APEC14B1 and have consented to testing through the Molecular Characterization Initiative (MCI), prior to enrollment on ANBL2131
* = 30 years at the time of initial diagnosis with high-risk disease
* * Must have a diagnosis of neuroblastoma (NBL) or ganglioneuroblastoma (nodular) verified by tumor pathology analysis or demonstration of clumps of tumor cells in bone marrow with elevated urinary catecholamines
* Newly diagnosed, high risk neuroblastoma (HRNBL) defined as one of the following:
* Any age with International Neuroblastoma Risk Group (INRG) Stage L2, MS, or M and MYCN amplification
* Age = 547 days and INRG stage M regardless of biologic features (clinical MYCN testing not required prior to enrollment)
* Any age initially diagnosed with INRG Stage L1 MYCN amplified NBL who have progressed to stage M without systemic chemotherapy
* Age = 547 days of age initially diagnosed with INRG Stage L1, L2, or MS who have progressed to stage M without systemic chemotherapy (clinical MYCN testing not required prior to enrollment)
* Patients must have a body surface area (BSA) = 0.25 m^2
* No prior anti-cancer therapy except as outlined below:
* Patients initially recognized to have high-risk disease treated with topotecan/cyclophosphamide initiated on an emergent basis and within allowed timing, and with consent
* Patients observed or treated with a single cycle of chemotherapy per a low or intermediate risk neuroblastoma regimen (e.g., as per ANBL0531, ANBL1232 or similar) for what initially appeared to be non-high-risk disease but subsequently found to meet the criteria
* Patients who received localized emergency radiation to sites of life threatening or function-threatening disease prior to or immediately after establishment of the definitive diagnosis
* Human immunodeficiency virus (HIV) -infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
* A serum creatinine based on age/sex as follows:
* 1 month to < 6 months: Male 0.4 mg/dL and female 0.4mg/dL
* 6 months to < 1 year: Male 0.5 mg/dL and female 0.5 mg/dL
* 1 to < 2 years: Male 0.6 mg/dL and female 0.6 mg/dL
* 2 to < 6 years: Male 0.8 mg/dL and female 0.8 mg/dL
* 6 to < 10 years: Male 1 mg/dL and female 1 mg/dL
* 10 to < 13 years: Male 1.2 mg/dL and female 1.2 mg/dL
* 13 to < 16 years: Male 1.5 mg/dL and female 1.4 mg/dL
* = 16 years: Male 1.7 mg/dL and female 1.4 mg/dL
* The threshold creatinine values were derived from the Schwartz formula for estimating glomerular filtration rate (GFR) utilizing child length and stature data published by the Centers for Disease Control (CDC)
* or a 24-hour urine creatinine clearance = 70 mL/min/1.73 m^2 or
* or a GFR = 70 mL/min/1.73 m^2. GFR must be performed using direct measurement with a nuclear blood sampling method or direct small molecule clearance method (iothalamate or other molecule per institutional standard)
* Note: Estimated GFR (eGFR) from serum creatinine, cystatin C or other estimates are not acceptable for determining eligibility
* Total bilirubin = 1.5 x upper limit of normal (ULN) for age
* Serum glutamic pyruvic transaminase (SGPT) (Alanine aminotransferase [ALT]) = 10 x ULN*
* Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L
* * Shortening fraction of = 27% by echocardiogram, or
* Ejection fraction of = 50% by echocardiogram or radionuclide angiogram
* Ability to tolerate Peripheral Blood Stem Cell (PBSC) collection:
No known contraindication to PBSC collection. Examples of contraindications might be a weight or size less than the collecting institution finds feasible, or a physical condition that would limit the ability of the child to undergo apheresis catheter placement (if necessary) and/or the apheresis procedure
Query!
Minimum age
No limit
Query!
Query!
Maximum age
30
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Patients who are 365-546 days of age with INRG Stage M and MYCN non-amplified NBL, irrespective of additional biologic features
* Patients = 547 days of age with INRG Stage L2, MYCN non-amplified NBL, regardless of additional biologic features
* Patients with known bone marrow failure syndromes
* Patients on chronic immunosuppressive medications (e.g., tacrolimus, cyclosporine, corticosteroids) for reasons other than prevention/treatment of allergic reactions and adrenal replacement therapy are not eligible. Topical and inhaled corticosteroids are acceptable
* Patients with a primary immunodeficiency syndrome who require ongoing immune globulin replacement therapy
* Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required prior to enrollment for female patients of childbearing potential
* Lactating females who plan to breastfeed their infants
* Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation
* All patients and/or their parents or legal guardians must sign a written informed consent
* All institutional, food and drug administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
19/04/2024
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
31/12/2029
Query!
Actual
Query!
Sample size
Target
478
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Query!
Recruitment hospital [1]
0
0
Sydney Children's Hospital - Randwick
Query!
Recruitment hospital [2]
0
0
The Children's Hospital at Westmead - Westmead
Query!
Recruitment hospital [3]
0
0
Queensland Children's Hospital - South Brisbane
Query!
Recruitment hospital [4]
0
0
Royal Children's Hospital - Parkville
Query!
Recruitment hospital [5]
0
0
Perth Children's Hospital - Perth
Query!
Recruitment postcode(s) [1]
0
0
2031 - Randwick
Query!
Recruitment postcode(s) [2]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [3]
0
0
4101 - South Brisbane
Query!
Recruitment postcode(s) [4]
0
0
3052 - Parkville
Query!
Recruitment postcode(s) [5]
0
0
6009 - Perth
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arkansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
California
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Colorado
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Connecticut
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Delaware
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
District of Columbia
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Florida
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Georgia
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Illinois
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Indiana
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Iowa
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Kansas
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Kentucky
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Louisiana
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Maine
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Maryland
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Massachusetts
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Michigan
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Minnesota
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Mississippi
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Missouri
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Nebraska
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
New Hampshire
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
New Jersey
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
New York
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
North Carolina
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
North Dakota
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
Ohio
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
Oklahoma
Query!
Country [32]
0
0
United States of America
Query!
State/province [32]
0
0
Oregon
Query!
Country [33]
0
0
United States of America
Query!
State/province [33]
0
0
Pennsylvania
Query!
Country [34]
0
0
United States of America
Query!
State/province [34]
0
0
Rhode Island
Query!
Country [35]
0
0
United States of America
Query!
State/province [35]
0
0
South Carolina
Query!
Country [36]
0
0
United States of America
Query!
State/province [36]
0
0
South Dakota
Query!
Country [37]
0
0
United States of America
Query!
State/province [37]
0
0
Tennessee
Query!
Country [38]
0
0
United States of America
Query!
State/province [38]
0
0
Texas
Query!
Country [39]
0
0
United States of America
Query!
State/province [39]
0
0
Utah
Query!
Country [40]
0
0
United States of America
Query!
State/province [40]
0
0
Virginia
Query!
Country [41]
0
0
United States of America
Query!
State/province [41]
0
0
Washington
Query!
Country [42]
0
0
United States of America
Query!
State/province [42]
0
0
Wisconsin
Query!
Country [43]
0
0
Canada
Query!
State/province [43]
0
0
Alberta
Query!
Country [44]
0
0
Canada
Query!
State/province [44]
0
0
British Columbia
Query!
Country [45]
0
0
Canada
Query!
State/province [45]
0
0
Manitoba
Query!
Country [46]
0
0
Canada
Query!
State/province [46]
0
0
Nova Scotia
Query!
Country [47]
0
0
Canada
Query!
State/province [47]
0
0
Ontario
Query!
Country [48]
0
0
Canada
Query!
State/province [48]
0
0
Quebec
Query!
Country [49]
0
0
Canada
Query!
State/province [49]
0
0
Saskatchewan
Query!
Country [50]
0
0
New Zealand
Query!
State/province [50]
0
0
Auckland
Query!
Funding & Sponsors
Primary sponsor type
Government body
Query!
Name
National Cancer Institute (NCI)
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neuroblastoma cells, but is not present on many healthy or normal cells in the body. When dinutuximab binds to the neuroblastoma cells, it helps signal the immune system to kill the tumor cells. This helps the cells of the immune system kill the cancer cells, this is a type of immunotherapy. When chemotherapy and immunotherapy are given together, during the same treatment cycle, it is called chemoimmunotherapy. This clinical trial randomly assigns patients to receive either standard chemotherapy and surgery or chemoimmunotherapy (chemotherapy plus dinutuximab) and surgery during Induction therapy. Chemotherapy drugs administered during Induction include, cyclophosphamide, topotecan, cisplatin, etoposide, vincristine, and doxorubicin. These drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. Upon completion of 5 cycles of Induction therapy, a disease evaluation is completed to determine how well the treatment worked. If the tumor responds to therapy, patients receive a tandem transplantation with stem cell rescue. If the tumor has little improvement or worsens, patients receive chemoimmunotherapy on Extended Induction. During Extended Induction, dinutuximab is given with irinotecan, temozolomide. Patients with a good response to therapy move on to Consolidation therapy, when very high doses of chemotherapy are given at two separate points to kill any remaining cancer cells. Following, transplant, radiation therapy is given to the site where the cancer originated (primary site) and to any other areas that are still active at the end of Induction. The final stage of therapy is Post-Consolidation. During Post-Consolidation, dinutuximab is given with isotretinoin, with the goal of maintaining the response achieved with the previous therapy. Adding dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy may be better at treating children with newly diagnosed high-risk neuroblastoma.
Query!
Trial website
https://clinicaltrials.gov/study/NCT06172296
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Sara M Federico
Query!
Address
0
0
Children's Oncology Group
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT06172296
Download to PDF